Can analysts adopt a bullish outlook for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)?

July 13, 2018 - By Joseph Norton

Investors sentiment increased to 1.43 in 2018 Q1. Its up 0.34, from 1.09 in 2017Q4. It is positive, as 12 investors sold ANI Pharmaceuticals, Inc. shares while 42 reduced holdings. 37 funds opened positions while 40 raised stakes. 6.72 million shares or 7.48% more from 6.25 million shares in 2017Q4 were reported.
Benjamin F Edwards And stated it has 0% in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Aperio Limited Liability Company invested in 4,780 shares or 0% of the stock. Parametric Port Associates Ltd Liability Corporation, a Washington-based fund reported 19,688 shares. Kansas-based Intrust Financial Bank Na has invested 0.12% in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). State Of Tennessee Treasury Department has 0% invested in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) for 6,404 shares. Globeflex Capital L P has invested 0.14% in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Jefferies Lc has 29,244 shares for 0.01% of their portfolio. Ameritas Investment Partners Inc stated it has 616 shares or 0% of all its holdings. New York State Common Retirement Fund accumulated 11,630 shares. Creative Planning holds 0% or 5,123 shares. Louisiana State Employees Retirement Sys stated it has 4,000 shares or 0.01% of all its holdings. Ls Ltd Liability holds 0.01% of its portfolio in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) for 1,754 shares. Millennium Management Ltd Liability Com has 47,544 shares for 0% of their portfolio. Jpmorgan Chase has invested 0% in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Regent Invest Mgmt has invested 0.71% of its portfolio in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP).

Since March 1, 2018, it had 0 insider buys, and 10 selling transactions for $18.16 million activity. On Wednesday, April 18 the insider MARSHBANKS TRACY sold $2.06M. $1.77 million worth of stock was sold by Schrepfer Robert W on Thursday, March 1. Marken James G. also sold $258,640 worth of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) on Monday, March 5. Another trade for 27,964 shares valued at $1.74 million was made by RAYNOR DANIEL on Monday, March 12.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Ratings Coverage

Among 2 analysts covering ANI Pharmaceuticals (NASDAQ:ANIP), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ANI Pharmaceuticals had 2 analyst reports since February 28, 2018 according to SRatingsIntel. Canaccord Genuity maintained it with “Buy” rating and $82 target in Wednesday, February 28 report. Cantor Fitzgerald initiated ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) rating on Monday, June 11. Cantor Fitzgerald has “Buy” rating and $8500 target. Below is a list of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) latest ratings and price target changes.

11/06/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $85.0000 Initiate
28/02/2018 Broker: Canaccord Genuity Old Rating: Buy New Rating: Buy Old Target: $77 New Target: $82 Maintain

The stock decreased 0.84% or $0.6 during the last trading session, reaching $70.68. About 24,673 shares traded. ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has risen 31.37% since July 13, 2017 and is uptrending. It has outperformed by 18.80% the S&P500.

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, makes, and markets branded and generic prescription pharmaceuticals in the United States. The company has market cap of $833.06 million. It focuses on producing controlled substances, anti-cancer , hormones and steroids, and complex formulations. It has a 35340 P/E ratio. The firm offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and Hydrocortisone Enema and Cortenema to treat ulcerative colitis.

More news for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) were recently published by: Nasdaq.com, which released: “Market Trends Toward New Normal in EnviroStar, Rowan Companies, Del Taco Restaurants, ANI Pharmaceuticals …” on June 25, 2018. Investorplace.com‘s article titled: “4 Undervalued MedTech Stocks to Consider Amid Volatility” and published on June 19, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.